DGAP-Adhoc
Epigenomics AG: Blitz F16-83 GmbH to launch takeover offer for Epigenomics AG
DGAP-Ad-hoc: Epigenomics AG / Key word(s): Takeover Publication of Inside Information according to Article 17 MAR |
Blitz F16-83 GmbH to launch takeover offer for Epigenomics AG
April 26, 2017 - Epigenomics AG (FSE: ECX; OTCQX: EPGNY) ("Epigenomics" or "Company"), Cathay Fortune International Company Limited ("CFIC") and Blitz F16-83 GmbH (in the future Summit Hero Holding GmbH, "Bidder"), a subsidiary of CFIC, have tonight entered into a business combination agreement ("BCA") regarding the takeover of Epigenomics by the Bidder. Other than by CFIC, the Bidder will also be indirectly owned by the largest current shareholder of Epigenomics, Biochain, the strategic partner of Epigenomics and a subsidiary of Team Curis Group.
Pursuant to the BCA, the Bidder has agreed to launch a voluntary public takeover offer pursuant to the German Takeover Act (Wertpapiererwerbs- und Übernahmeangebot - WpÜG) to acquire all of the outstanding ordinary shares of Epigenomics ("Takeover Offer").
Under the terms of the BCA, Epigenomics shareholders will be offered 7.52 Euros in cash per each ordinary share. The transaction values Epigenomics' equity, including net cash, at approximately 171 million Euros and reflects a 49.4% premium to the 3-month volume weighted average share price of 5.03 Euros (as published by Bloomberg.com) prior to announcement and a 51.9% premium to yesterday's XETRA-closing price of 4.95 Euros. The offer shall be subject to certain closing conditions, including regulatory approval and a minimum acceptance threshold of 75% of all of Epigenomics' outstanding shares.